RxDoctor Payments Data

Gregory Mula, MD

Gastroenterology · Hammond, LANPI 1265437362

Payments from drug & device makers

$4,159in general payments, 2019–2025

Across 289 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Bristol Myers Squibb$301
  • Sanofi$271
  • Gilead$244
  • Pfizer$189
  • Takeda Pharmaceuticals U.S.A., Inc.$150
  • plus $870 from 19 others

What the payments were for

  • Food & beverage$4,12799%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,159 in reported general payments places this provider in the 50th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$254,054
Medicare patients
740
Services billed
2,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide77$51,978
CreonLipase/Protease/Amylase11$18,051
Sucralfate97$6,576
Balsalazide Disodium29$4,184
Budesonide DrBudesonide33$3,900
Pantoprazole Sodium543$3,155
NexiumEsomeprazole Magnesium11$2,857
Lactulose63$2,252
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,790
CholestyramineCholestyramine (With Sugar)30$1,711
Famotidine138$1,244
Ondansetron OdtOndansetron262$1,047
Omeprazole63$976
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl45$872
Dicyclomine Hcl32$609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,135$70,02988 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Hammond

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →